JCR Pharmaceuticals and Acumen Pharmaceuticals formed a partnership to develop a brain delivery therapy.
4 reports, 4 independent
Updated Jun 16
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
JCR Pharmaceuticals and Acumen Pharmaceuticals formed a partnership to develop a brain delivery therapy.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.JCR provides J-Brain Cargo technology for ACU301/ACU401 candidates.1 source
Partnership announced between JCR and Acumen to develop brain delivery therapy.1 source
Keep exploring
The entities involved
-
JCR Pharmaceuticals
Nothing else this week.
-
Acumen Pharmaceuticals (United States)
company in Livermore, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- manilatimes.net
- Pharmaceutical TechnologyAcumen and JCR partner on brain delivery therapy for Alzheimer’s Acumen Pharmaceuticals has entered a partnership, option and licence agreement with JCR Pharmaceuticals to develop an oligomer-targete
- GlobeNewswireAcumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease Acumen and JCR aim to de
- Business WireJCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - Strategic partnership utilizes JCR’s